IGF-1 therapy for cystic fibrosis explored in 28-week pilot study targeting body weight and composition

Patients with Cystic Fibrosis (CF) often experience significant challenges with maintaining adequate body weight and lean mass, contributing to disease progression and poorer outcomes. This is frequently due to malabsorption, increased energy expenditure, and chronic inflammation. Current nutritional and therapeutic strategies often fall short in fully addressing these complex metabolic derangements. Insulin-like Growth Factor-1 (IGF-1) is a crucial anabolic hormone involved in growth, metabolism, and tissue repair, making it a compelling candidate to investigate for improving body composition and overall health in this vulnerable population.

This was a 28-week pilot study designed to examine the efficacy of recombinant human IGF-1 in adult patients diagnosed with Cystic Fibrosis. The primary endpoints focused on assessing changes in body weight and overall body composition. While specific dosing, route of administration, frequency, or the exact number of participants (n) were not detailed in the abstract, the study aimed to establish preliminary data on IGF-1's potential benefits in this patient group. No control arm or specific assay names were mentioned in the provided information.

The provided abstract describes the objective of a pilot study but does not include any specific findings, results, or statistical data. Therefore, no quantitative outcomes regarding the efficacy of IGF-1 on body weight or composition in adults with cystic fibrosis can be reported at this time. The study's aim was to examine these parameters, implying that results are pending or not yet published.